This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Pankit Vachhani, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Tania Jain, MBBS: ...

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed. Disease-free ...

Myelofibrosis involves driver mutations causing JAK-STAT pathway activation, leading to uncontrolled cell growth and various symptoms. JAK inhibitors like Rituxan, Inrebic, Vonjo, and Ojjaara target ...

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in ...

Add Us On GoogleAdd as a preferred source on Google (WNDU) - Your blood accounts for about 8% of your total body weight. It’s vital for life, but when cancer happens in the blood, it can become deadly ...

Cytopenia in myelofibrosis patients increases the risk of AML progression and decreases overall survival, necessitating careful treatment selection. A retrospective cohort study found 70% of ...

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol. The phase 3 ...

Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise. "I suspect that the incidence is actually higher than what we originally thought, not only ...